A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients

BMC Cancer

Research Article

Thomas Wolf¹  Ronald E. Myers¹  Stephen C. Peiper²  Scott A. Waldman³  Sarah Hegarty³  Phillip Shwae⁴ 

[1] Department of Medical Oncology, Thomas Jefferson University, Benjamin Franklin House, Suite 314, 834 Chestnut St, 19107, Philadelphia, PA, USA;Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Jeff Hall, Room 279, 1020 Locust St, 19107, Philadelphia, PA, USA;Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, 1015 Chestnut Street Building, Suite M-100 Mezzanine, 1015 Chestnut Street, 19107, Philadelphia, PA, USA;Thomas Jefferson University, 305 South 11th Street, Apt. 4F, 19107, Philadelphia, PA, USA;

关键词: Decision analysis;    Cancer;    Colon carcinogenesis;    Molecular genetics;    Staging;   

DOI  :  10.1186/s12885-016-2812-1

 received in 2015-10-12, accepted in 2016-09-23,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundWe sought to assess physician interest in molecular prognosic testing for patients with early stage colon cancer, and identify factors associated with the likelihood of test adoption.MethodsWe identified physicians who care for patients with early-stage (pN0) colon cancer patients, mailed them a survey, and analyzed survey responses to assess clinician receptivity to the use of a new molecular test (GUCY2C) that identifies patients at risk for recurrence, and clinician readiness to act on abnormal test results.ResultsOf 104 eligible potential respondents, 41 completed and returned the survey. Among responding physicians, 56 % were receptive to using the new prognostic test. Multivariable analyses showed that physicians in academic medical centers were significantly more receptive to molecular test use than those in non-academic settings.Forty-one percent of respondents were ready to act on abnormal molecular test results. Physicians who viewed current staging methods as inaccurate and were confident in their capacity to incorporate molecular testing in practice were more likely to say they would act on abnormal test results.ConclusionsPhysician receptivity to molecular diagnostic testing for early-stage colon cancer patients is likely to be influenced by practice setting and perceptions related to delivering quality care to patients.Trial registrationClinicalTrials.gov Identifier: NCT01972737

【 授权许可】

CC BY   
© The Author(s). 2016